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Summary
von Willebrand factor (VWF) is a multimeric glycoprotein that mediates platelet adhesion and is
decreased in von Willebrand disease (VWD). 1-8 deamino-D-arginine vasopressin (DDAVP), the
most common treatment for VWD, is limited by tachyphylaxis and inconvenience, and in 20% of
the patients, unresponsiveness. Recombinant human interleukin-11 (rhIL-11), a gp-130 signalling
cytokine with haematopoietic and anti-inflammatory activity, increases VWF antigen and its
activity in heterozygous VWF+/− mice and dogs. To determine the biological efficacy and safety
of rhIL-11 in non-bleeding human subjects with mild VWD, we conducted a phase II prospective
open-label trial of rhIL-11 at 10, 25 and 50 μg kg−1 subcutaneously (s.c.), given daily for 7 days in
nine subjects with mild VWD. VWF and factor VIII (FVIII) levels increased gradually and
progressively after s.c. rhIL-11, which was sustained through 7 days of dosing to 1.5- to 3-fold
over baseline. Following intravenous DDAVP, 0.3 μg kg−1, on day 7 there was a further boost in
VWF and FVIII levels, suggesting that the mechanism of rhIL-11 differs from that of DDAVP.
Platelet VWF mRNA expression measured by quantitative PCR increased from two- to eightfold
over baseline, suggesting that the mechanism of rhIL-11 effect may be upregulation of VWF
mRNA. VWF and FVIII levels returned to baseline by day 14. rhIL-11 was well tolerated with
less than grade-1 hypertension, hypokalaemia and fluid retention. Recombinant IL-11 increases
VWF levels in humans with mild VWD, justifying future clinical trials to determine its potential
in preventing or reducing bleeding in this patient population.
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Introduction
von Willebrand factor (VWF) is a multimeric plasma glycoprotein that mediates platelet
adhesion to vascular endothelium and serves as a carrier molecule for FVIII [1,2]. Decreased
VWF results in von Willebrand disease (VWD), a congenital bleeding disorder affecting 1%
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of the population [3], characterized by mucosal bleeding, including epistaxis, menorrhagia,
postoperative and excessive post-traumatic bleeding [4,5]. Current treatment with DDAVP,
which acts by stimulating release of VWF from endothelial stores in Weibel-Palade bodies,
is efficacious but limited by tachyphylaxis, inconvenience of intravenous (i.v.) infusion
especially in women with menorrhagia, the potential to induce hyponatraemia in children
and unresponsiveness in 15–20% of patients [5-7]. Plasma-derived VWF concentrate, an
alternative to DDAVP, is limited by higher cost and transmissible infectious agent risk [8].
Thus, development of safer, more effective products and alternative treatment strategies are
goals for improving treatment of VWD [9,10]. Recombinant human interleukin 11 (rhIL-11,
Neumega®; Wyeth Pharmaceuticals, Collegeville, PA, USA), a gp-130 signalling cytokine
with haematopoietic and anti-inflammatory activity, currently FDA-approved for
chemotherapy treatment of thrombocytopenia [11,12], has recently been shown to increase
VWF antigen and activity with good tolerance in mice, dogs and healthy volunteers, and in
heterozygous VWF+/− mice and dogs [13-15]. In the latter, the VWF increase was sustained
over a range of doses (25, 50 and 75 μg kg day−1), for as long as the drug was given [14,15],
suggesting the existence of a mechanism other than endothelial release [14,15], and the
potential of rhIL-11 as an alternative agent to treat VWD. Taken together, these data suggest
that rhIL-11 is a candidate as an alternative agent to treat human VWD. We therefore,
conducted a prospective open-label Phase II study of rhIL-11 in non-bleeding subjects with
mild VWD to test its biological efficacy and safety.
Materials and methods
Study subjects
Following signed informed consent, nine subjects 18 years of age or older with mild VWD,
classified as type 1 VWD by recently published NHLBI criteria [10], were enroled in and
completed the trial. Type 1 VWD was defined by the presence of a bleeding history; an
abnormal bleeding severity score (BS) [8], low VWF:RCo, and normal distribution of VWF
multimers [10]. All subjects had previous evidence of biological response to DDAVP, with
correction by VWF tests into the normal range. One subject, Pt 7, with von Willebrand
ristocetin cofactor (VWF:RCo) above 0.50 U mL−1, had a bleeding severity score of 6 and
belonged to a large VWD kindred with affected siblings and children, all with significant
bleeding, and thus was included, consistent with NHLBI criteria [10] as well as those in the
genotype-phenotype studies in Canada [16] and Europe [17]. The reduced VWF:RCo/
VWF:Ag ratios in Pt. 1, 2, 3, 7, 8 and 9 are also consistent with, but not diagnostic of type
2M VWD [10,16,17]. The presence of any of the other bleeding disorders, cardiac disease,
congestive failure, arrhythmia, hypertension, myocardial infarction, stroke, thrombosis or
past allergic reaction to rhIL-11 or DDAVP, or surgery within 8 weeks prior to study
constituted the exclusion criteria. Concomitant use of immunomodulatory or experimental
drugs, diuretics, antiplatelet drugs, anticoagulants, dextran, aspirin and non-steroidal anti-
inflammatory drugs were not allowed, nor was treatment with DDAVP, cryoprecipitate,
whole blood, plasma or plasma derivatives containing FVIII or VWF, within 5 days of
study. Females who were pregnant or lactating were excluded from the study, and no
hormone, oral contraceptive or other oestrogen use in the past 8 weeks was allowed.
Subjects recruited for this study included the first nine subjects who met all entry criteria
were willing to participate in this time-intensive study, and who in the judgement of the
investigators were able to comply with all study requirements. All subjects provided signed
informed consent in accordance with the Declaration of Helsinki. The protocol and informed
consent documents were approved by the Clinical Translational Research Center (CTRC)
Advisory Committee [formerly General Clinical Research Center (GCRC)] and the
Institutional Review Board (IRB) at the University of Pittsburgh.
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Study design and treatment schedule
This was a Phase II prospective open-label, escalating dose trial of rhIL-11. Three
consecutive subjects each were scheduled to receive rhIL-11 at 25, 50 and 75 μg kg−1
subcutaneously (s.c.) daily for 7 days (days 1–7), followed by DDAVP at 0.3 μg kg−1
intravenously 30 min after rhIL-11 on day 7. Because coagulation levels, including
VWF:RCo, VWF antigen (VWF:Ag), FVIII clotting activity (FVIII:C) and FVIII antigen
(FVIII:Ag), increased up to fourfold over baseline at the 50 μg kg−1 dose level, with no
toxicity, the 75 μg kg−1 dose level was removed; after discussion with the Data Safety
Monitoring Board, a 10 μg kg−1 dose level was added to establish a dose–response
relationship and avoid any potential toxicity at higher dose levels. Thus, the final three
subjects received rhIL-11 at 10 μg kg−1 according to the schedule above.
A medical history, physical examination, vital signs and fluid status assessment (height,
weight, cardiac-, lung-and fundoscopic exam) were performed at baseline and before and 30
min and 4 h after daily rhIL-11. The screening visit (day 0) and final visit (day 14) were
carried out at the Hemophilia Center of Western PA, and the biological effects study was
carried out at the Montefiore University Hospital Clinical & Translational Research Center
(MUH-CTRC), formerly the GCRC. Laboratory studies drawn at baseline and on day 1 (first
day of rhIL-11), day 4, day 7 and on day 14 included the following coagulation tests:
VWF:RCo, VWF:Ag, FVIII:C, FVIII:Ag, activated partial thromboplastin time (APTT),
VWF multimers and closure times with epinephrine (CEPI) or adenosine diphosphate
(CADP); clinical blood counts: haemoglobin, haematocrit and platelet count; and safety
tests: electrolytes, electrocardiogram (EKG) rhythm strip. Platelet-rich plasma for platelet
VWF mRNA was drawn at baseline, day 7 and day 14.
Dose escalation
The dose-limiting toxicity was defined as any grade 3 or higher treatment-related toxicity
possibly or probably related to the investigational drug. Specific dose-limiting toxicities
included persistent (>24 h) hyponatraemia (Na+ <130 mEq L−1) or hypokalaemia (K+ <3.5
mEq L−1), any platelet count >900,000, any grade 3 or higher treatment-related toxicity, or
recurrence of any of these criteria. Dose escalation was permitted only if the occurrence of
dose-limiting toxicity resolved within 24 h.
Laboratory assays
Plasma was assayed for VWF activity using ristocetin-induced platelet agglutination kits and
a Chronolog aggregometer (Chronolog Corp., Havertown, PA, USA). VWF:Ag was
determined by ‘sandwich’ ELISA as described [18-21]. The multimer distribution of
VWF:Ag was analysed by sodium dodecyl sulfate gel electrophoresis using 1.5% or 0.65%
agarose gels [18-20]. Anti-VWF antibodies used for VWF:Ag ELISA and multimer gels
were purchased from Dako (A0082; Carpinteria, CA, USA). The VWF:Ag concentration
and activity values are expressed in U mL−1, based on normal reference human plasma pool
(George King Biomedical, Inc., Overland Park, KS, USA) that was assigned a value of 1.00
U mL−1. Human severe type 3 VWD plasma, VWF:RCo 15 U mL−1 and VWF:Ag 1 U
mL−1 from one type 3 VWD patient (George King Bio-Medical, Inc) served as negative
control. FVIII:C was determined by chromogenic substrate assay (Coamatic Factor VIII;
DiaPharma Group, Westchester, OH, USA), as specified by the manufacturer. FVIII:C
activity is expressed in U mL−1 based on normal human reference plasma (George King).
FVIII:Ag was determined by immunoassay per the manufacturer’s instructions
(Asserochrome FVIII:Ag; Diagnostica Stago, Gennevilliers, France). Human haemophilia A
plasma served as negative control (George King Bio-Medical, Inc).
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Platelet-poor plasma for the above assays was prepared from citrated blood by
centrifugation at 1300 g for 15 min. The plasma was spun a second time at 1300 g for 7 min
and stored at −80°C for batch testing. The APTT was performed by commercial reagents on
an ST4 analyzer (Diagnostic Stago), and closure times, CEPI and CADP were performed by
PFA-100 analyzer (Dade Behring, Marburg, Germany). VWF mRNA was performed on a
lysed platelet pellet (prepared from platelet-rich plasma), the RNA was reverse transcribed
into cDNA and amplified by quantitative PCR for VWF mRNA expression. Platelet-rich
plasma was prepared from EDTA plasma by centrifugation at 250 g for 15 min at room
temperature. Platelets were pelleted at 1500 g for 10 min, the supernatant discarded and the
platelet pellet was stored at −80°C for batch testing. RNA isolation from the platelet pellet
was performed using Tri-Reagent, bromochloropropane and DNAse I (Sigma, St Louis,
MO, USA), and RNA quality was assessed by Nanodrop ND-1000 Spectrophotometer
(Applied Biosystems, Foster City, CA, USA) with all RNA analysed at 260/280 nm >1.8.
Real-time PCR was performed using High-Capacity cDNA Archive Kit and Taqman
Universal PCR Master Mix (Applied Biosystems) with the gene-specific validated Taqman
assays for VWF (Hs00169795_m1) and GPIBb (Hs02579226_s1). The VWF Taqman assay
utilized a primer set that produces a 79-bp amplicon spanning exons 17 and 18. The GP1Bb
Taqman assay produces a 178 bp amplicon spanning an exon 2 boundary. Both assays
amplify only the intact mRNAs. Samples were reverse transcribed for 10 min at 25°C and 2
h at 37°C, followed by 43 rounds of amplification for 15 s at 95°C and 1 min at 60°C using
the ABI Prism 7700 sequence detection system (Applied Biosystems). Quantification of the
gene-specific VWF message level was based on a relative quantification comparison of the
fluorescence intensity in the baseline (untreated) total RNA sample to the fluorescence
intensity from day 7 and day 14 (7 days following treatment) total RNA samples.
Amplification of the gene for GP1Bb, which is a constitutively expressed platelet-specific
gene, was performed on all samples tested to control for variations in the RNA amounts. The
VWF mRNA levels were subsequently normalized against the GP1Bb mRNA levels.
Endpoints and statistical methods
A minimum of nine evaluable subjects in this Phase II study was considered adequate to
provide sufficient power to evaluate biological efficacy of the study [22], specifically with
95% confidence to show an increase of 0.2 VWF U mL−1, with σ of 0.1 VWF U mL−1 at α
= 0.05 and β = 0.90 (one-sided). Because of the small sample size, descriptive statistics were
used to evaluate VWF and related factors. Statistical analyses for this study were based on
assessment of the primary endpoint, biological efficacy and secondary endpoint and safety.
Assessment of biological efficacy response to rhIL-11 was based on an increase in
VWF:RCo, VWF:Ag, FVIII:C and FVIII:Ag, assessed at baseline, day 1, 4 and 7, using
descriptive statistics. Assessment of safety was based on incidence rates of adverse events,
which were calculated as the number of subjects with an event divided by the number of
subjects exposed to drug. Incidence rates for adverse event episodes were calculated by the
number of adverse event cases over the number of doses. Adverse event incidence rates
were categorized by body system, relationship to study drug, severity of adverse event, age,
gender, time of onset of adverse event and duration of adverse event. Safety laboratory
variables were analysed by descriptive statistics. Comparisons between VWF and FVIII
activity and antigen levels by dose group were performed by t-test, comparing absolute
values to baseline after rhIL-11 and after DDAVP.
Safety analysis
Adverse events were assessed according to the NCI Common Terminology Criteria of
Adverse Events (CTCAE) Version 3.0 [23]. As part of the safety assessment, specific focus
was given to fluid retention and arrhythmias.
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A total of nine subjects with mild VWD, a past bleeding history and past DDAVP
responsiveness were enroled on study between October 2004 and December 2006. Median
age was 35 years (range 21 to 49 years) (Table 1).
Increase in VWF and FVIII Antigen and Activity in Response to IL-11 and DDAVP
There was an increase in VWF:RCo, VWF:Ag, FVIII:C and FVIII:Ag levels beginning at 24
h after rhIL-11, and persisting for the 7 days the drug was given. This increase was further
boosted on day 7 after DDAVP infusion. By day 4 at 30 min after rhIL-11 injection, mean
VWF:RCo was 1.49- to 1.62-fold higher than baseline, VWF:Ag was 1.56 to 2.19-fold
higher, FVIII:C was 1.26 to 1.93-fold higher and FVIII:Ag was 1.25 to 2.23-fold higher than
baseline levels, with significant increases in individual values (Tables 2 and 3). The effect
persisted at 4 h after rhIL-11 injection and through day 7 and was further boosted on day 7
by i.v. DDAVP at 0.3 μg kg−1 given 30 min after rhIL-11, with an increase in VWF:RCo,
1.58 to 3.15-fold higher than baseline; VWF:Ag, 1.91 to 2.96-fold higher; FVIII:C, 2.08 to
3.16-fold higher and FVIII:Ag, 2.92 to 3.82-fold higher than baseline. By day 14, 7 days
after the last dose of rhIL-11, VWF and FVIII levels returned to baseline. An example of the
temporal changes in VWF:RCo, VWF:Ag and FVIII:C in one subject after rhIL-11, after
DDAVP, and following cessation of the drug, is shown in Fig. 1
VWF Multimers following IL-11 and DDAVP
All patients had normal VWF multimer patterns at baseline, as analysed in 1.5% and 0.65%
agarose gels. On day 7, very high-molecular-weight VWF multimers appeared after
DDAVP, in parallel with the increase in plasma VWF antigen levels in all subjects and at all
three doses of rhIL-11, as shown in one subject (Fig. 2).
Platelet VWF mRNA by quantitative PCR
The increase in VWF was accompanied by a two- to eightfold increase in VWF mRNA
expression over baseline, by quantitative PCR, as shown in one subject (Fig. 3).
Adverse effects and safety of IL-11 and DDAVP
Recombinant human IL-11 was well tolerated with minor adverse effects, all less than grade
1 toxicity (Table 4). Minor adverse events included hypertension, fluid retention and
hypokalaemia, all less than grade 1 toxicity. Asymptomatic hypertension defined as diastolic
blood pressure of 90 mmHg or higher, occurred in three subjects at the two higher dose
levels, one of whom was found to have baseline labile hypertension. Fluid retention,
including ring finger swelling in two subjects at the two higher dose levels was self-limited,
and non-pitting oedema in a third subject on the 50 μg kg−1 dose arm resolved with oral
Lasix (Furosemide, Mylan Pharmaceuticals, Morgantown, WV, USA). Hypokalaemia
occurred in three subjects at the two high dose arms: the lowest potassium level, 3.1 mEq
L−1, was asymptomatic, caused no changes on EKG and resolved with orange juice. One
38-year-old male subject on the 50 μg kg−1 dose arm developed anxiety and atypical chest
pain, the evening before a scheduled visit. His chest X-ray, EKG, blood gases and spiral
computerized tomography scan were all negative, and his symptoms, which resolved
spontaneously without treatment, were judged to be unrelated to the study drug. There was a
mean 2.2-fold increase (P < 0.01) in fibrinogen by day 4, mean 349 to 671 mg dL−1, but no
thrombotic events occurred during the study.
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Platelet counts following rhIL-11
There was a delayed increase in platelet count following rhIL-11 treatment. By day 7, there
was a mean 19 ± 5% increase (not significant) and, by day 14, a 125 ± 15% increase (P <
0.001) in platelet count. The increase in platelet number on day 14 was by 66 000 to 183 000
μL−1, with the highest absolute platelet count not exceeding 492 000 μL−1. This increase in
platelets may have been, in part, reactive. Dilutional anaemia occurred in all subjects, with
an average 2.7 g% decrease in haemoglobin (range, 1.8 to 3.5%), concomitant with mild
fluid retention and, on average, a 0.9 kg weight gain (range, −0.5 to 1.9 kg). Both the weight
gain and dilutional anaemia resolved by day 14 (7 days after cessation of rhIL-11),
constituting less than grade 1 toxicity. There was no significant correlation between VWF
levels and platelet count at baseline, r = −0.30, P > 0.40; at day 7, r = 0.371, P > 0.50; or at
day 14, r = 0.099, P > 0.50.
Discussion and conclusion
This study demonstrates that rhIL-11 given s.c. causes a gradual and progressive increase in
VWF and FVIII levels in subjects with mild VWD. The VWF:RCo and VWF:Ag levels
increased 1.4 to 2.3-fold above baseline, sustained for the 7 days during which rhIL-11 was
given. On day 7 after DDAVP, there was release of very high-molecular weight VWF
multimers, confirmed on 0.65% agarose gel, which was not observed after rhIL-11 alone
(Fig. 2a,b). These data suggest that the mechanism of the rhIL-11-induced VWF increase
differs from that of DDAVP, and, specifically, that the rhIL-11-induced VWF increase
occurs by a mechanism other than through release of VWF from endothelial stores [6]. The
further boost in VWF and FVIII and release of very high-molecular weight VWF multimers
by DDAVP implies that the DDAVP-releasable VWF pool persists despite rhIL-11
treatment, and that there is little, if any, effect of rhIL-11 on VWF trafficking to endothelial
Weibel-Palade bodies, consistent with previous findings in dogs [15].
The two- to eightfold increase in VWF mRNA expression following rhIL-11 administration,
as demonstrated by quantitative PCR, implies that the mechanism of rhIL-11 effect may be
through upregulation of VWF mRNA. Previous studies in dogs have demonstrated a similar
increase in VWF mRNA following rhIL-11 injection [15], although this was not the case in
mice [14]. Whether rhIL-11 induces an increase in Weibel-Palade bodies or prevents loss of
responsiveness to DDAVP is not known [15].
The findings of this study also show that when DDAVP is given after seven consecutive
days of rhIL-11 treatment, VWF levels are increased above that induced by rhIL-11 alone,
suggesting that rhIL-11 may be a useful agent in those refractory or unresponsive to
DDAVP. It is unlikely, however, that the converse is true, i.e. that rhIL-11 boosts DDAVP
response, given the difference in mechanisms and temporal separation in responses:
DDAVP acts via a secretory pathway and induces an immediate release (within min) of
substantial amounts of stored, very high-molecular-weight multimers that are cleared over
the next 24 h, while rhIL-11 appears to induce a sustained increase in constitutive VWF
release that progressively increases over days.
The rhIL-11-induced increase in FVIII:C suggests rhIL-11 may be a potentially effective
haemostatic agent in mild haemophilia A. Further, the increase in FVIII:C after rhIL-11
injection appears to be to a lesser degree than the increase in VWF. Whether the increase in
FVIII:C occurs by a separate mechanism from that of the VWF increase, or whether it
involves upregulation of FVIII mRNA, however, remains unresolved.
While the site where FVIII and VWF first interact has not been established [24], recent data
in haemophilia liver transplant recipients suggest that co-localization of FVIII and VWF are
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necessary for FVIII secretion after DDAVP [25]. DDAVP is known to be a specific agonist
for the vasopressin V2 receptor (V2R) [26], and it is well established that with DDAVP
binding to endothelial V2R, VWF is secreted from endothelial Weibel-Palade bodies [27].
The mechanism of FVIII release, however, is not known, and further studies are needed to
clarify the mechanism of VWF and FVIII responses to rhIL-11 and DDAVP.
It should be noted that the baseline VWF:RCo and VWF:Ag levels measured at the start of
the study (Table 2) were higher than those measured at diagnosis (Table 1). The reasons for
this are not known but may relate to many factors. First, the study samples and diagnosis
samples were drawn on widely different days and at widely different times and run in
different laboratories. Day-to-day and lab-to-lab variability in VWF levels has been
previously described and likely to contribute to these differences [2]. Second, the acute
stress of an in-hospital research study of a new agent is also likely to contribute to these
differences. Notably, this study was performed in the CTRC at the University of Pittsburgh
which allowed all study blood samples to be drawn at the same time and all medications to
be given at the same time on each study day. Thus, we believe that the results showing an
increase in VWF activity, antigen and mRNA following rhIL-11 accurately reflect changes
induced by rhIL-11. Third, it should be noted that the FVIII increase after rhIL-11 in
subjects 6, 7 and 8 did not appear to increase sufficiently for potential surgical challenge. It
is not clear why the FVIII increase was inferior in these subjects to the VWF increase, but
could suggest potential increase in available VWF:Ag binding sites [2,10,28].
In summary, recombinant IL-11 is well tolerated and safely increases VWF and FVIII into
the range associated with clinical haemostasis in humans with mild VWD while not
bleeding. These data justify a clinical trial to determine whether rhIL-11 will reduce clinical
bleeding when present in this population or when procedures or surgery would be expected
to be associated with excessive bleeding. Those refractory to or with a limited response to
DDAVP might also benefit, and those who desire the safety of treatment with other than
plasma-derived concentrates would also be of interest to study. The potential target
population may include those with type 1 VWD or type 2M VWD, although, as genotyping
becomes more common, the full spectrum of those responsive to rhIL-11, just as with
DDAVP, will likely become evident [2]. Clinical trials to determine clinical efficacy of
rhIL-11 in VWD are underway.
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Temporal Change in von Willebrand factor (VWF) levels after rhIL-11 and 1-8 deamino-D-
arginine vasopressin (DDAVP). The fold-increase in VWF:RCo, FVIII:C, and VWF:Ag are
shown in one subject treated at dose I, the low dose level (10 μg kg−1), at baseline (white);
on day 1 at 30 min (pale grey) at 4 h (dark grey); day 4 at 30 min (pale diagonal stripe) at 4
h (dark diagonal stripe); on day 7 at 30 min after rhIL-11 (before DDAVP) (vertical stripe)
and 30 min after DDAVP (low density dots); and on day 14, 7 days after the last dose of
rhIL-11 (high density dots). vWF:RCo, von Willebrand ristocetin cofactor; VWF:Ag, von
Willebrand antigen, FVIII:C, clotting factor VIII; rhIL-11, recombinant human
interleukin-11.
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von Willebrand factor (VWF) multimers after rhIL-11 and 1-8 deamino-D-arginine
vasopressin (DDAVP). VWF multimer bands are shown from one subject treated at dose III,
the high dose level (50 μg kg−1), in 1.5% agarose (top panel) and in 0.65% agarose (lower
panel), with separation of low (L), medium (M), high (H), and very high (VH) multimers.
The first lane is normal pooled plasma (NPP), the positive control. The second lane is
plasma from a type 3 severe patient with von Willebrand disease (VWF:RCo 15 U mL−1,
VWF:Ag U mL−1), the negative control. In the next lanes are screening; day 1 and day 4,
pre and 30 min and 4 h post-rhIL-11; and day 7 pre-rhIL-11, post-IL-11, and 30 min and 4 h
post-DDAVP. Very high-molecular-weight multimers were detected on day 7 after DDAVP
treatment (indicated by arrowhead). In the last lane on day 14, very high-molecular-weight
multimers returned to the baseline. vWF:RCo, von Willebrand ristocetin cofactor; VWF:Ag,
von Willebrand antigen; VWF:Ag, von Willebrand antigen; rhIL-11, recombinant human
interleukin-11.
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Platelet von Willebrand factor (VWF) mRNA expression after rhIL-11. Platelet VWF
mRNA from one subject treated at dose I, the low dose level (10 μg kg−1), was isolated from
platelet-rich plasma and reverse transcribed into VWF cDNA, and then amplified by
quantitative PCR (see methods). When no RNA template was added, no reaction occurred
and no message was detected, as seen in the yellow line. After rhIL-11, there was no change
in GPIBb expression, as seen in the nearly superimposed green (baseline) and blue (after
rhIL-11) lines. By contrast, after rhIL-11, there was a two- to eightfold increase in VWF
mRNA expression as seen by the increase from brown (baseline) to red (after rhIL-11) lines
(see arrow). NTC, no template control; rhIL-11, recombinant human interleukin-11.
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Table 3
Per cent increase in VWF and FVIII activity and antigen after recombinant IL-11.
Dose I (10 μg kg−1) Dose II (25 μg kg−1) Dose III (50 μg kg−1)
Mean level (per cent over baseline)
VWF:RCo
 Day 1, pre 85 (68–98)† 72 (45–100) 114 (57–160)
 Day 1, 30 min 104 (122%) 81 (112%) 105 (92%)
 Day 4, 30 min 138 (162%) 107 (149%) 179 (157)
 Day 7, 30 min 152 (179%) 81 (144%) 179 (157)
 Day 7, after DDAVP 267 (314%)* 114 (158%) 359 (315)
VWF:Ag
 Day 1, pre 101.8(67.6–139.2) 59.1 (48.7–75.1) 109.5 (53.0–204.3)
 Day 1, 30 min 120.0 (118%) 32.0 (54%) 116.3 (106%)
 Day 4, 30 min 158.6 (156%) 101.8 (172%) 240.3 (219%)
 Day 7, 30 min 154.5 (152%) 104.9 (177%) 206.3 (188%)
 Day 7, after DDAVP 301.5 (296%)* 113.2 (191%) 276.8 (253%)*
FVIII:C
 Day 1, pre 147.9 (115.8–202.2) 59.4 (16.2–99.5) 46.7 (10.9–101.1)
 Day 1, 30 min 155.2 (105%) 47.2 (79%) 42.7 (91%)
 Day 4, 30 min 186.2 (126%) 114.8 (193%) 64.9 (139%)
 Day 7, 30 min 199.5 (135%) 67.9 (114%) 68.7 (147%)
 Day 7, after DDAVP 307.9 (208%) 164.4 (277%) 147.8 (316%)
FVIII:Ag
 Day 1, pre 97.8 (74.0–129.8) 57.8 (18.1–79.6) 36.1 (8.2–62.2)
 Day 1, 30 min 93.9 (96%) 42.9 (74%) 29.1 (81%)
 Day 4, 30 min 146.9 (150%) 129.0 (223%) 45.1 (125%)
 Day 7, 30 min 143.9 (147%) 131.1 (227%) 48.5 (134%)
 Day 7, after DDAVP 295.5 (302%)** 221.1 (382%) 105.4 (292%)
DDAVP, 1-8 deamino-D-arginine vasopressin; VWF, von Willebrand factor; VWF:RCo, von Willebrand ristocetin cofactor; IL, interleukin;
FVIII:C, clotting factor VIII; Ag, antigen.
†
Range in parentheses. Statistical significance is indicated by
*
for P < 0.01 and
**
for P < 0.05.
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Table 4
Safety and tolerance of rhIL-11 in study subjects.
Dose I (10 μg kg−1) Dose II (25 μg kg−1) Dose III (50 μg kg−1)
Hypertension
 No. abnormal 0 2* 1
 Median diastolic BP, mmHg 84 91 81
Hypokalaemia, No.
 No. abnormal† 0 1 2
 Median K+, mEq L−1 3.5 3.5 3.2
Fluid retention‡
 No. abnormal† 0 1 2
 Median weight gain, kg 1.7 0.7 0.8
Anaemia, dilutional
 No. abnormal† 3 3 3
 Median haemoglobin, g dL−1 10.2 12.1 12.6
Secondary thrombocytosis§
 No. abnormal† 1 0 0
 Median platelet no. × 103 μL−1 390 367 320¶
BP, blood pressure.
*
One subject (25 μg kg−1 dose) had baseline labile hypertension.
†
Abnormal tests in each category listed above were all less than grade 1 toxicity.
‡
Fluid retention included ring finger swelling (one each, 25 and 50 μg kg−1 doses) and non-pitting pedal oedema (one, 50 μg kg−1 dose).
§
At 14 or 7 days after last rhIL-11 injection.
¶
One subject (50 μg kg−1 dose) had baseline thrombocytopenia related to hepatitis C infection.
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